First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 61
• 5 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute myeloid leukemia that came back or did not respond to treatment, or with high or very-high risk myelodysplastic syndromes. It tests the safety of ABD-3001 for the first time in people.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Relapsed or refractory acute myeloid leukemia, or high or very-high risk myelodysplastic syndromes. The record states that people cannot receive intensive or new generation targeted therapy.

Read by machine on 9 Nov 2026.

Sites (5)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details